Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1280607

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1280607

mRNA Platform

PUBLISHED:
PAGES: 334 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 5600
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 16800

Add to Cart

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global mRNA Platform Market to Reach $120.1 Billion by 2030

In the changed post COVID-19 business landscape, the global market for mRNA Platform estimated at US$136.2 billion in the year 2022, is projected to decline to US$120.1 Billion by 2030, exhibiting a compounded average rate of decline of -1.6% over the analysis period 2022-2030. Covid-19 Vaccine, one of the segments analyzed in the report, will witness the steepest decline of -4.2% to reach US$96.5 Billion by the end of the analysis period. The decline is led by the waning pandemic, lower disease severity and reduced reliance on vaccines. The Cancer Vaccine segment, on the other hand, will continue to witness robust growth and reach US$18.3 billion over the next 8-year period.

The U.S. Market is Estimated at $61.6 Billion, While China is Forecast to Grow at 0.9% CAGR

The mRNA Platform market in the U.S. is estimated at US$61.6 Billion in the year 2022 and will continue to decline at a rate of -1.8% over the analysis period. China, the world`s second largest economy, is forecast to reach a projected market size of US$13.7 Billion by the year 2030 trailing a CAGR of 0.9% over the analysis period 2022 to 2030. Rest of Asia-Pacific (excluding China) will remain the only other regional market to witness a positive growth of 0.5% over the analysis period to reach a projected market value of US$8.9 billion by 2030. Canada and Japan will each decline at -3.3% and -2.8% respectively over the 2022-2030 period.

Select Competitors (Total 96 Featured) -

  • AstraZeneca PLC
  • Asuragen, Inc.
  • Catalent Pharma Solutions
  • Altogen Labs
  • Arcturus Therapeutics, Inc.
  • BioNTech AG
  • CRISPR Therapeutics
  • Aldevron
  • AKESOgen, Inc.
  • baseclick GmbH
  • chimeron bio
  • Acuitas Therapeutics
  • Accent Therapeutics
  • Accanis Biotech F&E GmbH & Co KG
  • Avectas
Product Code: MCP23108

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Impact of Covid-19 and a Looming Global Recession
    • The Race Between the Virus & Vaccines Intensifies
    • Effectiveness of Vaccinations
    • Covid-19 Vaccine Shortages Hit Global Supply Initiative
    • Saving Lives with Vaccines
    • Dosing Interval Adjustment to Expand Coverage
    • Global COVID-19 Vaccine Inequity
    • Accessibility of Vaccines
    • Impact of Vaccine Inequity on the Economy
    • Impact of Vaccine Inequity on the Labor Market
    • Financing Vaccines
    • mRNA Platform - Global Key Competitors Percentage Market Share in 2023 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2023 (E)
  • MRNA - A CONCEPTUAL UNDERSTANDING
    • MRNA: A New Approach to Medicine
    • Long Wait & Scientific Breakthroughs
    • mRNA Vaccines - An Introduction
    • With Unparalleled Turnaround Time, mRNA Platform Adds Revolutionary Dimension to Vaccine Development
    • mRNA: Making Cells Act as Vaccine Factory
    • mRNA Vaccines: Advantages
    • mRNA Vaccines: Cons
    • mRNA Vaccine Approvals
    • A Comparison of Pfizer, Moderna, and AstraZeneca COVID-19 Vaccine
    • Traditional Vs. mRNA Vaccines: Key Differences
    • Traditional Vs. mRNA Vaccines: The Development Process
    • How mRNA Vaccine Works & Earlier Testing Efforts
    • mRNA Vaccines: Safety Quotient
    • Other Notable Efforts Centered on mRNA Technology
    • Overcoming Challenges
    • As Serious Candidate, mRNA Technology Warrants Attention from Scientific Community
  • GLOBAL MARKET OVERVIEW
    • Global mRNA Vaccines Market on a Dynamic Growth Track
    • Riding COVID-19 Wave, mRNA Vaccines Take Center Stage & See Exciting Times Ahead
    • COVID-19 mRNA Vaccine Approval Details
    • COVID-19 Funding Details of Moderna and Pfizer Vaccine
    • Production Capacity of mRNA Frontrunners in Millions of Doses for 2021
    • COVID-19 Pandemic: An Eventful Year for RNA
    • COVID-19 Cases Worldwide by Country: As on May 17, 2021
    • COVID-19's Impact on Vaccine Development - A Transformative Shift to mRNA vaccines
    • mRNA Based Vaccines in Clinical Development
    • mRNA Vaccines in Phase IV Clinical Trials
    • mRNA Vaccines in Phase III Clinical Trials
    • mRNA Vaccines in Phase II Clinical Trials
    • Vaccines in Pipeline by Technology
    • Vaccine Technologies in Pre-Clinical Studies
  • VARIOUS VIRUS VARIANTS
    • COVID-19 Virus Can Adapt & Undergo 'Escape Mutation' to Pose Vaccine Challenge
    • Indian Variant of COVID-19 Virus Puts Healthcare System on Brink of Major Collapse
    • Investigating the Virulence Profile of India's N440K Variant
    • Is South African Variant a Formidable Threat?
    • E484K Mutation Challenges Vaccine Developers
    • Rising Cases in South Africa & Other Countries
    • California Strain Emerges to be More Contagious and Deadly
    • Pfizer COVID-19 Vaccine Demonstrates Low to Modest Level of Efficacy against South African Variant
    • Pfizer/BioNTech Trailing a Third Covid-19 Shot to Provide Variant Protection
    • Moderna's Variant-Specific Vaccine Candidate Ready for Clinical Study
    • mRNA Vaccines Could Vanquish Cancer and Other Diseases, Cancer Segment to Make Major Contribution to Global mRNA Vaccines Market
    • The US Holds Leading Position, while Asia-Pacific Exhibits Lucrative Growth in mRNA Vaccines Market
    • Faster, Effective and Cheaper: Adaptability of mRNA Vaccine Unleashes Potential Utility for Developing Nations
    • RECENT MARKET ACTIVITY IN THE COVID-19 VACCINE SPACE
    • Pfizer and BioNTech's COVID-19 Vaccine Receives World's First Authorization
    • UK Clinches the First Position in the World to Approve Pfizer's Vaccine
    • After UK, US Gives Nod to Pfizer's Vaccine
    • EU Approves Pfizer's Vaccine
    • BioNTech to Scale up Vaccine Production to Fill Supply Gaps and Support Vaccination Efforts in the EU
    • Novartis Inks Agreement with Pfizer-BioNtech to Support Covid-19 Vaccine Production
    • FDA Approves Pfizer-BioNTech Vaccine in Kids aged 12 to 15 Years Age (May, 2021)
    • Moderna's mRNA Vaccine Bags Approval from US FDA
    • Moderna Kick-Starts Inoculation in the US
    • FDA Approves Pfizer-BioNTech Vaccine in Kids aged 12 to 15 Years Age (May, 2021)
    • Moderna Begins Testing its Vaccine on Children Aged Below 12 Years (March, 2021)
    • Recent Market Activity
  • COMPETITIVE SCENARIO
    • BioNTech - A Pioneer in mRNA-based Vaccines and Therapies
    • List of BioNTech's mRNA Candidates in Clinical Trials for Cancer
    • Moderna's Ambitious Stride into Vaccine Development: From a Novice to Know All
    • Moderna's mRNA Prophylactic Vaccines
    • mRNA Cancer Vaccines
    • mRNA Intratumoral Immuno-Oncology
    • mRNA Systemic Secreted & Cell Surface Therapeutics
    • mRNA Systemic Intracellular Therapeutics
    • Sanofi Commences Clinical Trials of mRNA vaccine for Covid-19
    • mRNA as Promising Vaccine Technology Entices Startups to Join the Bandwagon
    • Noteworthy Startups Exploiting mRNA Technology
    • Providence Therapeutics
    • pHion Therapeutics
    • eTheRNA immunotherapies & 20Med Therapeutics
    • The East Falls behind the West in Embracing the Revolutionary mRNA Technology for Developing Vaccines to Fight against COVID-19
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Coronavirus Cases Drive the Market Demand
    • Increasing Prevalence of Infectious & Chronic Conditions to Unleash Gains & Help mRNA Vaccines Market Gallop Ahead
    • mRNA Vaccines Development for Other Infectious Diseases and Therapeutic Areas Gains Momentum
    • Worldwide Cancer Incidence: Number of New Cancer Cases Diagnosed for 2012, 2018 & 2040
    • Global HIV Prevalence: Number of People Living with AIDs (in Thousands) by Region for 2018
    • Number of AIDS-Related Deaths (in Thousands) by Region for 2018
    • Aging Demographics Add to the Global Burden of Chronic Diseases, Presenting Opportunities for the Market
    • Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
    • Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
    • Increasing Healthcare Expenditure to Foster Market Growth
    • World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
    • Healthcare Costs as a % of GDP by Country for the Years 2020 & 2023
    • Consistent Increase in Risks and Threats from Infections Drive Healthy Market Growth
    • Global Number of Deaths Caused Due to Communicable Diseases (In 000s)
    • Regulatory Landscape for mRNA Vaccines
    • Regulatory Pathway Dealing with mRNA Vaccines
    • mRNA Vaccine Patent Scenario
    • The Best Route of Administration for mRNA Vaccines
    • CDC Study on Vaccine Effectiveness States mRNA Vaccines Offer More Protective Benefits than other Vaccines (March, 2021)
    • mRNA CANCER VACCINES
    • Introduction
    • Cancer Vaccines Vs. Immunotherapies
    • Clinical Trials of mRNA Encoding Immunostimulants
    • mRNA Vaccines Vs. DNA Vaccines
    • Clinical Trials of mRNA Encoding TAAs
    • mRNA Vaccines Vs. Other Vaccines
    • Clinical Trials of mRNA Vaccines Encoding Neoantigens (Neo-Ag)
    • mRNA Benefits Profile
    • mRNA Vaccines for Covid-19 Pave the Way
    • Challenges
    • Personalized mRNA Vaccine
    • Clinical Overview of mRNA Cancer Vaccines
    • mRNA encoding Immunostimulants
    • mRNA vaccine encoding tumor-associated antigens
    • mRNA vaccine encoding Neoantigen, personalized vaccine
    • mRNA Influenza Vaccines
    • Perpetual Evolution of Influenza Viruses Makes mRNA a Fascinating Vaccine Platform
    • Vaccines Built on mRNA
    • Clinical Trials for mRNA Vaccines
    • mRNA Vaccine as Game Changer for Flu Viruses Eluding Conventional Vaccine Efforts
    • mRNA: A Next-Generation Vaccination Approach
    • Moderna Moves Ahead to Brew Novel mRNA Vaccines for Influenza & Other Viruses
    • COVID-19 Vaccine Technology to Foster Development of Effective Flu Shots
    • mRNA Vaccines Vs. Other Flu Shots
    • mRNA Technology, H/N Spike Proteins & Clinical Trials
    • mRNA Technology: A Suitable Candidate for Universal & Effective Influenza Vaccines
    • Benefits & Limitations of mRNA Vaccines over Traditional Options
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World mRNA Platform Market Analysis of Annual Sales in US$ Million for Years 2021 through 2027
    • TABLE 2: World Recent Past, Current & Future Analysis for mRNA Platform by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2027 and % CAGR
    • TABLE 3: World 5-Year Perspective for mRNA Platform by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2023 & 2027
    • TABLE 4: World Recent Past, Current & Future Analysis for Covid-19 Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2027 and % CAGR
    • TABLE 5: World 5-Year Perspective for Covid-19 Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2027
    • TABLE 6: World Recent Past, Current & Future Analysis for Cancer Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2027 and % CAGR
    • TABLE 7: World 5-Year Perspective for Cancer Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2027
    • TABLE 8: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2027 and % CAGR
    • TABLE 9: World 5-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • mRNA Platform Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • US FDA Gives Nod to Pfizer and Moderna's mRNA Vaccines
    • Moderna to Supply 100 Million more Doses of COVID-19 Vaccine to the US Government
    • Lonza Announces Plans to Double Moderna COVID-19 Vaccine Output in Switzerland
    • US Regulators Give Nod to Pfizer-BioNTech COVID-19 Vaccine for Ages 12 to 15
    • Sanofi Joins Hands with Moderna to Produce COVID-19 Vaccines for Global Supply
    • TABLE 10: USA Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2027 and % CAGR
    • TABLE 11: USA 5-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2023 & 2027
  • CANADA
    • Vaccination Gathers Steam Across Canada
    • Percentage (%) of Population Vaccinated (at least one dose) in Canada by Province/Territory As of May 3, 2021
    • COVID-19 Vaccine Deals in Canada
    • Pfizer Plans to Ramp up COVID-19 Vaccine Supply to Canada from May, 2021
    • Canada Grants Approval to Pfizer's COVID-19 Shot for Use in Children in 12-15 Years Age Group
    • TABLE 12: Canada Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2027 and % CAGR
    • TABLE 13: Canada 5-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2023 & 2027
  • JAPAN
    • mRNA Platform Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • COVID-19 Vaccination Programs in Japan Move Forward at Snail's Pace
    • Reasons Responsible for Setback
    • Vaccine Timeline & Availability
    • Japan Demands for Vaccine-Related Data
    • People's Low Trust in Vaccines
    • Japan's Efforts to Develop Indigenous Vaccines
    • Japan to Step Up COVID-19 Immunization Drive to Cover Geriatric Population
    • Japan Inks Deal with Pfizer to Secure 50 Million Additional Doses of COVID-19 Vaccine
    • Japan Pushes Shipments of Pfizer's COVID-19 Shots to Vaccinate Elderly
    • TABLE 14: Japan Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2027 and % CAGR
    • TABLE 15: Japan 5-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2023 & 2027
  • CHINA
    • mRNA Platform Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • BioNTech's Shot to Become First Western COVID-19 Vaccine to Secure Authorization in China
    • TABLE 16: China Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2027 and % CAGR
    • TABLE 17: China 5-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2023 & 2027
  • EUROPE
    • mRNA Platform Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • EU Urges Nations to Focus on COVID-19 Vaccine Sharing & Export to Beat the Pandemic (May, 2021)
    • COVID-19 Vaccine Drive Gathers Pace in Europe after Initial Glitch
    • EU Approves Pfizer's Vaccine
    • EU Eyes on Milestone Deal to Get 1.8 Billion Doses of Pfizer-BioNTech COVID-19 Vaccine
    • European Agency Makes Changes to Ramp Up Supply & Manufacturing Capacity of Pfizer & Moderna COVID-19 Vaccines
    • BioNTech to Scale up Vaccine Production to Fill Supply Gaps and Support Vaccination Efforts in the EU
    • TABLE 18: Europe Recent Past, Current & Future Analysis for mRNA Platform by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2027 and % CAGR
    • TABLE 19: Europe 5-Year Perspective for mRNA Platform by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2023 & 2027
    • TABLE 20: Europe Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2027 and % CAGR
    • TABLE 21: Europe 5-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2023 & 2027
  • FRANCE
    • mRNA Platform Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 22: France Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2027 and % CAGR
    • TABLE 23: France 5-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2023 & 2027
  • GERMANY
    • mRNA Platform Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 24: Germany Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2027 and % CAGR
    • TABLE 25: Germany 5-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2023 & 2027
  • ITALY
    • Italy Plans to Produce mRNA Vaccines Domestically
    • TABLE 26: Italy Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2027 and % CAGR
    • TABLE 27: Italy 5-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2023 & 2027
  • UNITED KINGDOM
    • mRNA Platform Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • Market Analysis
    • UK Wins COVID-19 Vaccine Race with Approval of Pfizer-BioNTech Vaccine
    • Moderna Modifies Supply Contract with UK to Deliver Additional Doses of COVID-19 Vaccine
    • UK's Independent Vaccine Deals
    • TABLE 28: UK Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2027 and % CAGR
    • TABLE 29: UK 5-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2023 & 2027
  • REST OF EUROPE
    • TABLE 30: Rest of Europe Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2027 and % CAGR
    • TABLE 31: Rest of Europe 5-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2023 & 2027
  • ASIA-PACIFIC
    • mRNA Platform Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
  • INDIA
    • Pfizer Looks Forward to Make its COVID-19 Vaccine Available in India
  • AUSTRALIA
    • Australia to Buy 20 Million Extra Doses of Pfizer COVID-19 Vaccine, Pivoting away from AstraZeneca
  • NEW ZEALAND
    • New Zealand Acquires Ultra-Cold Freezers to Store Pfizer's COVID-19 Vaccine
    • TABLE 32: Asia-Pacific Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2027 and % CAGR
    • TABLE 33: Asia-Pacific 5-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2023 & 2027
  • REST OF WORLD
  • THE MIDDLE EAST
  • BAHRAIN
    • Bahrain Becomes the Second Country to Offer Emergency Use Approval to Pfizer's Vaccine
  • AFRICA
  • SOUTH AFRICA
    • New Virus Variant in South Africa Creates a Challenge
    • Highly Infectious COVID-19 Variant Spurs Countries to Impose Travel Ban from South Africa
  • LATIN AMERICA
    • Mass COVID-19 Vaccination Campaigns Launched in Latin American Countries
  • BRAZIL
    • Brazil Signs Deal to Buy Additional 100 Million Doses from Pfizer/BioNTech
  • MEXICO
    • Mexico's Cofepris Approves Emergency Use of Pfizer's COVID-19 Vaccine
    • TABLE 34: Rest of World Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2027 and % CAGR
    • TABLE 35: Rest of World 5-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2023 & 2027

IV. COMPETITION

Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!